Short answer: the FDA's fragrance allergen proposal is scheduled on the federal agenda for November 2026, and it is still a proposal, so nothing about US fragrance labeling has changed yet. The useful preparation is documentary: establishing what is inside your fragrance compounds, at what concentration in the finished product, and who in the supply chain holds that answer.
There is a particular kind of compliance work that produces no visible change on a label and no certificate to file, but decides whether a relabeling project takes three weeks or three months. Fragrance allergen disclosure is that work. The rule that would require it does not exist yet, which is exactly why the preparatory step is cheap now and expensive later.
This guide is about the document chain rather than the chemistry: what is scheduled, why the answer sits with a party that is usually not the brand, and what to request before the next production run puts labels on press.
What is scheduled, and what has not happened
The Modernization of Cosmetics Regulation Act directed the FDA to write a rule identifying which fragrance allergens must be disclosed on cosmetic labels, with a statutory deadline for the proposal in mid-2024. That deadline was missed. The item has since been carried on the federal Unified Agenda at the proposed-rule stage with a notice of proposed rulemaking timetabled for November 2026, and the agency has confirmed in public presentations during 2026 that the rule remains in development.
Two points of context matter more than the date itself.
The rule is a proposal when it appears, not a finished obligation. A notice of proposed rulemaking opens a comment period, and the final rule can arrive later and differ from the proposal. Nothing becomes unlawful in November, and a brand that reads the agenda as a compliance date will spend money in the wrong order.
The current position is lawful and will remain lawful until a final rule applies. Fragrance and flavor ingredients may be declared simply as "fragrance" or "flavor", and the labeling statute cannot be used to compel disclosure of a trade secret. A brand that concludes there is nothing to prepare has read the current rule correctly and the planning question incorrectly.
The direction, however, has been visible for several years. Regulators have been closing the gap between what a label says and what a product actually contains, and the fragrance blend is the largest remaining example of that gap in a cosmetic formula. The same pressure shows up in the parts of MoCRA that are already beyond the proposal stage, where registration, listing and adverse event reporting are operating obligations rather than future ones.
Why this is a document problem
An ingredient list is written by a brand from a formula. A fragrance declaration cannot be written the same way, because the fragrance is not a single ingredient in the ordinary sense — it is a concentrate, typically supplied under a confidentiality arrangement, and the composition of that concentrate is held by the house that created it, not by the brand whose name is on the carton and frequently not by the factory either.
Two consequences follow, and they are the reason this subject gets its own guide:
- The brand owns the obligation but does not own the data. Under MoCRA, the responsible person is the manufacturer, packer or distributor named on the label. On a private label or white label range, that is the brand. Product listing, safety substantiation, labeling compliance and serious adverse event reporting sit there, while facility registration belongs to the factory. Neither party can perform the other's role.
- The data has a threshold dimension. Disclosure regimes work on concentration in the finished product, not on the neat fragrance. The number a brand needs is the allergen percentage as delivered in the formula, which means the request has to travel from the brand to the factory to the fragrance house and back with arithmetic attached.
Neither of those is difficult. Both are slow when they are started late, and both are impossible to accelerate once label plates exist.
Who holds which document
The single most useful planning exercise is to write down which party holds each piece, because the gaps are usually at the handover points rather than inside any one company.
| Document | Held by | Why the brand needs it |
|---|---|---|
| Quantitative allergen breakdown for a named fragrance compound | The fragrance house | Thresholds are applied to the compound at its use level, so the neat-fragrance specification is not sufficient on its own |
| Allergen concentration in the finished formula | The factory, working from the fragrance data and the formula | This is the number that decides whether a name appears on the ingredient list |
| Current INCI declaration as manufactured | The factory | Any reformulation or supplier change silently invalidates an older declaration |
| Artwork with room for a longer ingredient list | The brand | Adding several allergen lines is a typographic problem before it is a regulatory one |
| Safety assessment reflecting the current documentation | The brand's safety assessor | The file that supports the product has to describe the product as formulated |
| Facility registration identifier for the manufacturing site | The factory | Separate from, and additional to, the brand's own listing obligation |
Two lines in that table are the ones that decide the schedule. The allergen breakdown is the only item that cannot be produced internally, and the artwork is the only item that cannot be fixed by email. Everything else is assembly.
The EU version already shows the shape of the file
For brands that sell on both sides of the Atlantic, the useful news is that the file largely exists already. The EU's expanded fragrance allergen list has been mandatory for products newly placed on that market since 31 July 2026, with a sell-off allowance for stock placed before that date. A brand that has already run its formula against the EU list therefore holds the allergen percentages it would need for a US rule — and a brand that has not is about to discover the gap twice.
The differences are concentrated in three places rather than in the data itself: which substances are on the list, what the applicable thresholds are, and what counts as a new placing on the market. The detail that catches private label buyers is the third one. Taking a stock formulation, putting your own name on it and shipping it can count as a new product being placed on the market, which means the compliance date is not inherited from the factory's original launch. The EU allergen thresholds and dates are worth checking before a shared formula is used for a second market; and the broader US filing picture sits in our MoCRA guide for importers.
Three reprint triggers that make this expensive
Cost in this area is rarely the data. It is the printing.
- Artwork space. A carton designed around a single "fragrance" entry may have no physical room for eight more lines at the required type size. On a small tube or a compact, that is a structural redesign rather than a text edit.
- Plates, cylinders and screens. Every decorated component carries its own tooling for the print method. Redoing all of them because one change arrived after they were made is the expensive version of a free change.
- Stock already in the channel. Product that has been filled and boxed is a decision rather than an edit: sell it through, rework it, or write it down.
The pattern is consistent. A change made before printing costs a revision. The same change made after printing costs the print run, which is why the natural moment to collect allergen data is the formula freeze rather than the label proof.
What to request before the next production run
Four requests, all of which can be made by email:
- An allergen declaration per fragrance compound, with concentrations in the finished formula. Not an IFRA certificate, and not a neat-compound specification — those answer a different question.
- A named owner for fragrance data updates, on the factory side and on the fragrance house side, with an agreed response time when a list changes. The failure mode here is not refusal; it is a request that arrives at a supplier who no longer has the original point of contact.
- A confirmation that current artwork can absorb a longer ingredient list, so that the typographic problem surfaces while it is still a design decision.
- A formula-level decision on fragrance variants. A range with two scent options has a shorter allergen workload than the same range with six scents sourced from three houses. That choice is made at formulation, months before anyone designs a carton, and it is cheaper to make deliberately than to discover.
None of this requires the rule to exist. All of it is reusable if the rule changes shape, because the underlying question — what is in this fragrance, and at what concentration — is the same question every disclosure regime asks. For brands with a US launch in the next two quarters, the sequencing that works is to collect the data at formula freeze, keep the ingredient list in a form that can be regenerated rather than hand-edited, and treat the label as the last artifact of the project instead of the first.
FAQ
Q: Has US fragrance allergen labeling changed as a result of the November 2026 agenda entry? A: No. The agenda entry describes an intended notice of proposed rulemaking, and until a final rule applies, fragrance and flavor ingredients may continue to be declared simply as "fragrance" or "flavor".
Q: Who is responsible for fragrance allergen disclosure on a private label product? A: The responsible person under MoCRA is the manufacturer, packer or distributor named on the label, which on a private label range is normally the brand. That party carries product listing, safety substantiation, labeling compliance and serious adverse event reporting, while facility registration sits with the factory.
Q: Why is a fragrance certificate not enough to answer an allergen question? A: Because disclosure thresholds are applied to the allergen's concentration in the finished product. A specification for the neat fragrance compound does not contain the arithmetic that connects it to the formula at use level, so the request has to reach the fragrance house through the factory.
Q: When is the cheapest moment to collect fragrance allergen data? A: At formula freeze. The data itself is inexpensive to obtain at any time, but a change that arrives after cartons and decorated components have been printed turns into a print-run cost, and product already filled and boxed becomes a commercial decision rather than an editorial one.